Idioma:

Gene Delivery to Joints by Intra-Articular Injection

Evans, Christopher H ; Ghivizzani, Steven C ; Robbins, Paul D

Human gene therapy, 2018-01, Vol.29 (1), p.2-14 [Periódico revisado por pares]

United States: Mary Ann Liebert, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Gene Delivery to Joints by Intra-Articular Injection
Autor: Evans, Christopher H ; Ghivizzani, Steven C ; Robbins, Paul D
Assuntos: Animal models ; Animals ; Arthritis ; Arthritis, Rheumatoid - genetics ; Arthritis, Rheumatoid - therapy ; Biocompatibility ; Biomedical materials ; Cartilage ; Cartilage (articular) ; Cartilage diseases ; Chondrocytes ; Clinical trials ; Delivery scheduling ; Dependovirus - genetics ; Drug delivery systems ; Drugs ; Gene therapy ; Gene transfer ; Gene Transfer Techniques ; Genetic Therapy - methods ; Genetic Vectors ; Humans ; Injection ; Injections, Intra-Articular ; Interferon ; Interleukin 1 ; Interleukin 1 receptor antagonist ; Interleukins ; Joint diseases ; Knee ; Medical research ; Medical treatment ; Metabolism ; Models, Animal ; Osteoarthritis ; Osteoarthritis - genetics ; Osteoarthritis - therapy ; Pathophysiology ; Pharmacokinetics ; Pharmacology ; Proteins ; Retroviridae - genetics ; Review ; Rheumatoid arthritis ; Ribonucleic acid ; RNA ; Transforming growth factor-a ; Transgenes ; Viruses
É parte de: Human gene therapy, 2018-01, Vol.29 (1), p.2-14
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Descrição: Most forms of arthritis are incurable, difficult to treat, and a major cause of disability in Western countries. Better local treatment of arthritis is impaired by the pharmacokinetics of the joint that make it very difficult to deliver drugs to joints at sustained, therapeutic concentrations. This is especially true of biologic drugs, such as proteins and RNA, many of which show great promise in preclinical studies. Gene transfer provides a strategy for overcoming this limitation. The basic concept is to deliver cDNAs encoding therapeutic products by direct intra-articular injection, leading to sustained, endogenous synthesis of the gene products within the joint. Proof of concept has been achieved for both in vivo and ex vivo gene delivery using a variety of vectors, genes, and cells in several different animal models. There have been a small number of clinical trials for rheumatoid arthritis (RA) and osteoarthritis (OA) using retrovirus vectors for ex vivo gene delivery and adeno-associated virus (AAV) for in vivo delivery. AAV is of particular interest because, unlike other viral vectors, it is able to penetrate deep within articular cartilage and transduce chondrocytes in situ. This property is of particular importance in OA, where changes in chondrocyte metabolism are thought to be fundamental to the pathophysiology of the disease. Authorities in Korea have recently approved the world's first arthritis gene therapy. This targets OA by the injection of allogeneic chondrocytes that have been transduced with a retrovirus carrying transforming growth factor-β cDNA. Phase III studies are scheduled to start in the United States soon. Meanwhile, two additional Phase I trials are listed on Clinicaltrials.gov , both using AAV. One targets RA by transferring interferon-β, and the other targets OA by transferring interleukin-1 receptor antagonist. The field is thus gaining momentum and promises to improve the treatment of these common and debilitating diseases.
Editor: United States: Mary Ann Liebert, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 18 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Gene Delivery to Joints by Intra-Articular Injection

Evans, Christopher H ; Ghivizzani, Steven C ; Robbins, Paul D

United States: Mary Ann Liebert, Inc

Buscando em bases de dados remotas. Favor aguardar.